University of Illinois Medical Center
Chicago, Illinois, 60612, United States
NCT Number: NCT00174538
The objective of this study is to determine if a subject's genetic make-up would affect the treatment response to codeine in subjects with sickle cell disease.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Phase 1 / Phase 2
Chicago, Illinois, 60612, United States
People with sickle cell disease require oral pain medications to manage an acute pain crisis. Sometimes these individuals fail to obtain adequate pain relief with the medications prescribed for outpatient use resulting in emergency room visits and hospital admissions. Subsequently, many patients are admitted to the hospital for pain management for a few days until the pain crisis resolves. The most common medications prescribed to sickle cell individuals for outpatient use include codeine and hydrocodone containing medications (i.e. Tylenol #3™, Vicodin™, Lortab™). These medications must be broken down in the body to make the active pain reliever (morphine or hydromorphone, respectively). Some individuals may not be able to break down these medications to the active pain reliever; therefore, these individuals will likely continue to experience pain unless they take other pain medications. We will determine whether genotype estimates the ability of CYP2D6 to break down codeine to the active pain reliever in individuals with sickle cell disease.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
PriCara, Unit of Ortho-McNeil, Inc.
Industry
The Effects of Cytochrome P450 2D6 Genotype on Pain Management With Codeine in Sickle Cell Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03049475
Anemia, Anemia, Hemolytic
Bethesda, Maryland, United States
View Trial DetailsNCT04417673
Anemia, Anemia, Hemolytic
Bethesda, Maryland, United States
View Trial DetailsNCT01757418
Anemia, Anemia, Hemolytic
The Bronx, New York, United States
View Trial DetailsNCT06580067
Anemia, Anemia, Hemolytic
Gainesville, Florida, United States
View Trial Details